The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co BMY reporting forecast-beating earnings.

Intec Pharma Ltd NTEC and Marinus Pharmaceuticals Inc MRNS lost much of their market value this week on clinical trial setbacks.

The following are some of the key biotech catalysts in the upcoming week:

Conferences

• 2nd Annual Biotechnology Congress: July 29-30 in Chicago.
• 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden.
• 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago.

Clinical Trial Readouts (mid-2019 releases)

• Immunic Inc IMUX: interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis.
• Conatus Pharmaceuticals Inc CNAT: 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
• Alkermes Plc ALKS: Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis.
• IMMUTEP LTD/S ADR IMMP: initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer.
• Aevi Genomic Medicine Inc GNMX: Phase 1b data for AEVI-002 in pediatric onset Crohn's disease.
• Tricida Inc TCDA: 12-month registration stability data from a Phase 3 study of TRC 101 in chronic kidney disease.
• Curis, Inc. CRIS: Phase 1 data for CA-4948 in relapsed or refractory non-Hodgkin lymphoma.
• Ultragenyx Pharmaceutical Inc RARE: Phase 1/2 data from a second cohort that is evaluating its DTX401 in Glycogen storage disease type 1 and Phase 1/2 third cohort data for DTX301 in ornithine transcarbamylase.
• Allakos Inc ALLK: Phase 2 top-line data for AK002 in eosinophilic gastritis.
• Leap Therapeutics Inc LPTXV: Phase 1/2 data for DKN-01 plus Keytruda in esophagogastric adenocarcinoma.
• Cidara Therapeutics Inc CDTX: Phase 2 data for rezafungin in candidemia.
• Akcea Therapeutics Inc AKCA: Phase 3 data for volanesorsen in familial partial lipodystrophy.
• Deciphera Pharmaceuticals Inc DCPH and Zai Lab Ltd ZLAB: Phase 3 data for DCC-2618 from a study dubbed INVICTUS in gastrointestinal stromal tumors
• ZEALAND PHARMA/S ADR ZEAL: Phase 1b data for dasiglucagon in obesity/diabetes.
• Aclaris Therapeutics Inc ACRS: Phase 2 open label 6-month data for ATI-502 in vitiligo and Phase 2 data for ATI-502 in atopic dermatitis.
• AnaptysBio Inc ANAB: Phase 2 data for ANB019 in generalized pustular psoriasis.
• Spark Therapeutics Inc ONCE: additional Phase 1/2 data for SPK-8011 in hemophilia A

Earnings

Monday, July 29

• Medpace Holdings Inc MEDP (before the market open)
• Alimera Sciences Inc ALIM (after the market close)
• Neurocrine Biosciences, Inc. NBIX (after the market close)
• Silk Road Medical Inc SILK (after the market close)

Tuesday, July 30

• Eli Lilly And Co LLY (before the market open)
• Iradimed Corp IRMD (before the market open)
• Blueprint Medicines Corp BPMC (before the market open)
• Meridian Bioscience, Inc. VIVO (before the market open)
• Merck & Co., Inc. MRK (before the market open)
• Incyte Corporation INCY (before the market open)
• Infinity Pharmaceuticals Inc. INFI (before the market open)
• NeoGenomics, Inc. NEO (before the market open)
• Pfizer Inc. PFE (before the market open)
• Amgen, Inc. AMGN (after the market close)
• AtriCure Inc. ATRC (after the market close)
• EXACT Sciences Corporation EXAS (after the market close)
• T2 Biosystems Inc TTOO (after the market close)
• BioTelemetry Inc BEAT (after the market close)
• Gilead Sciences, Inc. GILD (after the market close)
• Ironwood Pharmaceuticals, Inc. IRWD (after the market close)
• Veracyte Inc VCYT (after the market close)

Wednesday, July 31

• Amarin Corporation plc AMRN (before the market open)
• Strongbridge Biopharma plc SBBP (before the market open)
• United Therapeutics Corporation UTHR (before the market open)
• Nuvectra Corp NVTR (after the market close)
• ACADIA Pharmaceuticals Inc. ACAD (after the market close)
• Exelixis, Inc. EXEL (after the market close)
• DexCom, Inc. DXCM (after the market close)
• Vanda Pharmaceuticals Inc. VNDA (after the market close)
• MacroGenics Inc MGNX (after the market close)
• Vertex Pharmaceuticals Incorporated VRTX (after the market close)
• SurModics, Inc. SRDX (after the market close)

Thursday, Aug. 1

• Lexicon Pharmaceuticals, Inc. LXRX (before the market open)
• Akorn, Inc. AKRX (before the market open)
• ABIOMED, Inc. ABMD (before the market open)
• Agios Pharmaceuticals Inc AGIO (before the market open)
• Clovis Oncology Inc CLVS (before the market open)
• Concert Pharmaceuticals Inc CNCE (before the market open)
• Syros Pharmaceuticals Inc SYRS (before the market open)
• Insmed Incorporated INSM (before the market open)
• Intellia Therapeutics Inc NTLA (before the market open)
• Genomic Health, Inc. GHDX (after the market close)
• Acorda Therapeutics Inc ACOR (after the market close)
• Emergent Biosolutions Inc EBS (after the market close)
• BioMarin Pharmaceutical Inc. BMRN (after the market close)
• Coherus Biosciences Inc CHRS (after the market close)
• Kindred Biosciences Inc KIN (after the market close)
• Bio-Rad Laboratories, Inc. BIO (after the market close)
• Geron Corporation GERN (after the market close)
• Corvus Pharmaceuticals Inc CRVS (after the market close)
• CareDx Inc CDNA (after the market close)
• Globus Medical Inc GMED (after the market close)
• Verastem Inc VSTM (after the market close)
• Ultragenyx (after the market close)
• Kura Oncology Inc KURA (after the market close)

Friday, Aug. 2

• Momenta Pharmaceuticals, Inc. MNTA (before the market open)

IPO

Rapt Therapeutics, a biotech company developing therapies for inflammatory diseases and cancer, is set to offer 5 million shares at an estimated price range of $14-$16. The company proposes to list its shares on the Nasdaq under the ticker symbol "RAPT."